CA-INSPUR-INFORMATION
23.3.2022 09:11:08 CET | Business Wire | Press release
Inspur Information, a leading IT infrastructure provider, launched the new A6 server line that supports 3rd Gen AMD® EPYCTM Milan/Milan-X 7003 series processors. The A6 server line features multi-core capabilities that show outstanding performance leaps compared to previous generation of servers with an up to 28% performance increase in SPEC performance test. The A6 server line will serve as the foundation for compute-intensive applications in the enterprise scenarios, such as big data, multi-cloud and other high-demand computing applications.
“By launching the brand new A6 servers, Inspur aims to deliver better compute performance for reliable and efficient business support. The Inspur A6 server series features best-in-class performance, energy efficiency and scalability to address the enormous computing challenges imposed by the era of big data and digital transformation”, said Ricky Zhao, Deputy General Manager of Server Product Line and General Manager of Datacenter Product Line, Inspur Information.
“AMD has been collaborating with Inspur to deliver innovative and high-performance products to the market”, said Roger Benson, Senior Director of AMD. “The new A6 server line powered by AMD EPYCTM Milan/Milan-X 7003 series processors represents the latest achievement by AMD and Inspur. With multi-core configurations and a series of performance optimizations, this server solution will unleash more possibilities for handling complex and compute-intensive workloads.”
A6 servers showcase outstanding performance with multiple cores with a high-base frequency, providing industry-leading single core capabilities. Storage density and IOPS (input/output operations per second) are increased by more than threefold. With the precision engineering and multi-level security mechanisms, A6 servers are more intelligent, easy-to-use and safer. They ensure efficient and care-free operation. It is designed with open computing standards, such as the ORS6000E rack.
A6 servers are designed to provide ultimate performance
NF3180A6/ NF3280A6 is a 1U/2U 1S rack server based on 3rd Gen AMD® EPYCTM Milan processors. Powered by multiple cores with a high-base frequency, it can serve as a high-density and cost-effective rack server that delivers strong computing power comparable to traditional dual-socket servers. With the addition of flexible expansion, it can fulfill the specific requirements for cloud computing, distributed storage, big data, CDN, video transcoding, in-memory database and virtualization scenarios.
Inspur NF5180A6/NF5280A6, powered by 3rd Gen AMD® EPYCTM processors, is a high-density dual-socket server that offers strong computing performance, ecological compatibility and configuration flexibility. This server features high quality and strong reliability, which makes it the ideal choice for a variety of complicated workloads, especially data processing, virtualization, high performance and cloud computing.
Inspur i24A6 is a 2U4N multi-node server adopting AMD EPYC™ 7002/7003 processors. It has 24 storage drives, multiple network options, and 8x 3200 MHz RDIMM/LRDIMM. It is tailored for high-performance computing and hyper-scale, and other tasks that require high core counts, large storage capacity and flexible I/O solutions.
Inheriting the design DNA of Inspur Information’s renowned server products, the A6 server line represents industry-leading performance, design and security. The line will serve as an engine to promote industrial AI and digital transformation by offering a foundation for a variety of key scenarios including multi-cloud, high-performance computing and edge computing.
About Inspur Information
Inspur Information is a leading provider of data center infrastructure, cloud computing, and AI solutions. It is the world’s 2nd largest server manufacturer. Through engineering and innovation, Inspur Information delivers cutting-edge computing hardware design and extensive product offerings to address important technology sectors such as open computing, cloud data center, AI, and deep learning. Performance-optimized and purpose-built, our world-class solutions empower customers to tackle specific workloads and real-world challenges. To learn more, visit https://www.inspursystems.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005391/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom